These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

222 related items for PubMed ID: 20438763

  • 1. Characterization of HIV-1 resistance to a fusion inhibitor, N36, derived from the gp41 amino-terminal heptad repeat.
    Izumi K, Nakamura S, Nakano H, Shimura K, Sakagami Y, Oishi S, Uchiyama S, Ohkubo T, Kobayashi Y, Fujii N, Matsuoka M, Kodama EN.
    Antiviral Res; 2010 Aug; 87(2):179-86. PubMed ID: 20438763
    [Abstract] [Full Text] [Related]

  • 2. Mutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp41 and Rev-responsive element functions.
    Nameki D, Kodama E, Ikeuchi M, Mabuchi N, Otaka A, Tamamura H, Ohno M, Fujii N, Matsuoka M.
    J Virol; 2005 Jan; 79(2):764-70. PubMed ID: 15613304
    [Abstract] [Full Text] [Related]

  • 3. The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors.
    Gallo SA, Sackett K, Rawat SS, Shai Y, Blumenthal R.
    J Mol Biol; 2004 Jun 25; 340(1):9-14. PubMed ID: 15184018
    [Abstract] [Full Text] [Related]

  • 4. Differential inhibition of HIV-1 and SIV envelope-mediated cell fusion by C34 peptides derived from the C-terminal heptad repeat of gp41 from diverse strains of HIV-1, HIV-2, and SIV.
    Gustchina E, Hummer G, Bewley CA, Clore GM.
    J Med Chem; 2005 Apr 21; 48(8):3036-44. PubMed ID: 15828842
    [Abstract] [Full Text] [Related]

  • 5. Electrostatically constrained alpha-helical peptide inhibits replication of HIV-1 resistant to enfuvirtide.
    Nishikawa H, Nakamura S, Kodama E, Ito S, Kajiwara K, Izumi K, Sakagami Y, Oishi S, Ohkubo T, Kobayashi Y, Otaka A, Fujii N, Matsuoka M.
    Int J Biochem Cell Biol; 2009 Apr 21; 41(4):891-9. PubMed ID: 18834950
    [Abstract] [Full Text] [Related]

  • 6. Design and evaluation of antiretroviral peptides corresponding to the C-terminal heptad repeat region (C-HR) of human immunodeficiency virus type 1 envelope glycoprotein gp41.
    Soonthornsata B, Tian YS, Utachee P, Sapsutthipas S, Isarangkura-na-Ayuthaya P, Auwanit W, Takagi T, Ikuta K, Sawanpanyalert P, Kawashita N, Kameoka M.
    Virology; 2010 Sep 15; 405(1):157-64. PubMed ID: 20580393
    [Abstract] [Full Text] [Related]

  • 7. HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain.
    Lu L, Tong P, Yu X, Pan C, Zou P, Chen YH, Jiang S.
    Biochim Biophys Acta; 2012 Dec 15; 1818(12):2950-7. PubMed ID: 22867851
    [Abstract] [Full Text] [Related]

  • 8. A salt bridge between an N-terminal coiled coil of gp41 and an antiviral agent targeted to the gp41 core is important for anti-HIV-1 activity.
    Jiang S, Debnath AK.
    Biochem Biophys Res Commun; 2000 Apr 02; 270(1):153-7. PubMed ID: 10733920
    [Abstract] [Full Text] [Related]

  • 9. N36, a synthetic N-terminal heptad repeat domain of the HIV-1 envelope protein gp41, is an activator of human phagocytes.
    Le Y, Jiang S, Hu J, Gong W, Su S, Dunlop NM, Shen W, Li B, Ming Wang J.
    Clin Immunol; 2000 Sep 02; 96(3):236-42. PubMed ID: 10964542
    [Abstract] [Full Text] [Related]

  • 10. Chemoenzymatic synthesis of HIV-1 gp41 glycopeptides: effects of glycosylation on the anti-HIV activity and alpha-helix bundle-forming ability of peptide C34.
    Wang LX, Song H, Liu S, Lu H, Jiang S, Ni J, Li H.
    Chembiochem; 2005 Jun 02; 6(6):1068-74. PubMed ID: 15883971
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Genetic Pathway of HIV-1 Resistance to Novel Fusion Inhibitors Targeting the Gp41 Pocket.
    Su Y, Chong H, Xiong S, Qiao Y, Qiu Z, He Y.
    J Virol; 2015 Dec 02; 89(24):12467-79. PubMed ID: 26446597
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A time-resolved fluorescence assay to identify small-molecule inhibitors of HIV-1 fusion.
    Dams G, Van Acker K, Gustin E, Vereycken I, Bunkens L, Holemans P, Smeulders L, Clayton R, Ohagen A, Hertogs K.
    J Biomol Screen; 2007 Sep 02; 12(6):865-74. PubMed ID: 17644771
    [Abstract] [Full Text] [Related]

  • 18. Alanine scanning mutagenesis of HIV-1 gp41 heptad repeat 1: insight into the gp120-gp41 interaction.
    Sen J, Yan T, Wang J, Rong L, Tao L, Caffrey M.
    Biochemistry; 2010 Jun 22; 49(24):5057-65. PubMed ID: 20481578
    [Abstract] [Full Text] [Related]

  • 19. Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.
    Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M.
    J Biol Chem; 2009 Feb 20; 284(8):4914-20. PubMed ID: 19073606
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.